$LLY Recent News Drug-maker earnings come in ahead of

New Post Public Reply Private Reply Replies (0) Message Board

Nov 9, 2013 at 9:24 AM

$LLY Recent News

Drug-maker earnings come in ahead of views, but stocks aren't rewarded 10:45 a.m. Oct. 23, 2013 - Russ Britt
Stock futures retreat; Cat misses on earnings 7:42 a.m. Oct. 23, 2013 - William L. Watts
Eli Lilly net profit down 9.3%, revenue rises 6:03 a.m. Oct. 23, 2013 - MarketWatch.com
Eli Lilly 3Q adj. EPS FactSet estimate was $1.04 5:39 a.m. Oct. 23, 2013 - Sara Sjolin
Eli Lilly 3Q revenue up 6% to $5.77 billion 5:38 a.m. Oct. 23, 2013 - Sara Sjolin
Eli Lilly 3Q net income down 9% to $1.20 billion 5:37 a.m. Oct. 23, 2013 - Sara Sjolin
Eli Lilly 3Q adj. EPS up 41% to $1.11 5:35 a.m. Oct. 23, 2013 - Sara Sjolin
Boeing, AT&T, Caterpillar are stocks to watch 4:31 a.m. Oct. 23, 2013 - Sue Chang
The market in a minute: Playing with volatility 7:42 a.m. Oct. 21, 2013 - The Trading Deck
Eli Lilly downgraded to underperform by Jefferies 8:21 a.m. Oct. 11, 2013 - Ben Eisen
Tesla stuck in reverse, Herbalife loses momentum 3:35 p.m. Oct. 3, 2013 - Sue Chang
Lilly unveils $5 billion share-buyback program 7:02 a.m. Oct. 3, 2013 - MarketWatch.com
J.C. Penney snaps losing streak; Facebook tops $50 3:36 p.m. Sept. 26, 2013 - Sue Chang
3 dividend stocks for worried investors 5:00 a.m. Sept. 9, 2013 - Jeff Reeves
Renaissance Technologies' top dividend picks 3:25 p.m. Aug. 23, 2013 - Insider Monkey
Tuesday’s movers: Airline stocks, Apple 3:32 p.m. Aug. 13, 2013 - Maria LaMagna
U.S. stocks rise with help from Apple Inc. 3:21 p.m. Aug. 13, 2013 - Kate Gibson
Updates, advisories and surprises 5:01 p.m. July 24, 2013 - MarketWatch
Lilly shares up on higher earnings, lower expenses; Elan also rises 11:00 a.m. July 24, 2013 - Russ Britt
Apple, AT&T, Boeing are stocks to watch Wednesday 8:24 a.m. July 24, 2013 - Maria LaMagna

4 Healthcare Sector Dogs Hype 13% To 17% October Upsides; 4% To 7.5% Downsides 7:02 p.m. Nov. 8, 2013 - Seeking Alpha
Multiple Reasons To Buy Incyte 3:25 p.m. Nov. 8, 2013 - Seeking Alpha
Lower-than-Expected Loss at OncoGenex - Analyst Blog 3:20 p.m. Nov. 8, 2013 - Zacks.com
Eli Lilly Goes Down The Hill As Patents Expire 1:46 p.m. Nov. 8, 2013 - Seeking Alpha
3 Huge Healthcare Trends Can Fatten Your Portfolio 4:00 a.m. Nov. 8, 2013 - InvestorPlace.com
Stocks to Sell or Short: The Seven Least Preferred Stocks at UBS 8:28 a.m. Nov. 7, 2013 - 247WallSt.com
China Drags on Western Profits 12:23 a.m. Nov. 6, 2013 - WSJ.com
Prolific Selling - Hussman's High-Impact Moves Mirror Insiders 9:51 a.m. Nov. 5, 2013 - GuruFocus.com
We Like What We're Seeing In Big Pharma 4:15 a.m. Nov. 5, 2013 - Seeking Alpha
Drug Makers Get a Shot in the Arm 7:26 p.m. Nov. 3, 2013 - WSJ.com
Merck - Surprised Weakness In JANUVIA Is Causing Renewed Worries For Investors 2:10 p.m. Oct. 29, 2013 - Seeking Alpha
Eli Lilly Bulls: How Will 2014 Treat You? 10:08 a.m. Oct. 29, 2013 - Seeking Alpha
'Fast Money' Recap: Apple to the Core 5:00 a.m. Oct. 29, 2013 - TheStreet.com
Merck Profit Falls on Lower Sales 1:32 p.m. Oct. 28, 2013 - WSJ.com
Eli Lilly: Cymbalta Patent Expiry Quantified 12:48 p.m. Oct. 28, 2013 - Seeking Alpha
Narrower-than-Expected Q3 Loss at ImmunoGen - Analyst Blog 10:30 a.m. Oct. 28, 2013 - Zacks.com
4 Biotech Stocks Making Headlines 10:25 a.m. Oct. 28, 2013 - Wall St. Cheat Sheet
Our Retirement Income Portfolio And Its 3rd Quarter Review 4:22 p.m. Oct. 25, 2013 - Seeking Alpha
Apple’s Mavericks Breaks Records, JPMorgan’s Legal Concerns, and 3 More Hot Stocks 1:37 p.m. Oct. 25, 2013 - Wall St. Cheat Sheet
Amarantus' LymPro May Be More Crucial For Alzheimer's Treatment Than We Think 8:38 a.m. Oct. 25, 2013 - Seeking Alpha

Morning Research: Eli Lilly & Co., Bristol-Myers Squibb Co., Allergan Inc., and Endo Health Solutions Inc. 11:27 a.m. Nov. 4, 2013 - PR Newswire
Fitch: Pharmaceutical Cost Cutting Still Includes R&D for Some 11:18 a.m. Nov. 4, 2013 - BusinessWire
Through 2022, Growth in the Neuropathic Pain Drug Market Will be Constrained by the Genericization of Sales-Leading Agents from Eli Lilly/Shionogi, Endo/Grunenthal and Pfizer 9:00 a.m. Nov. 4, 2013 - PR Newswire
Medtronic, Lilly Diabetes Join Together as First Ever National Presenting Sponsors of the JDRF Walk To Cure Diabetes 9:00 a.m. Nov. 1, 2013 - PR Newswire
Dividend, Quarterly Report, Recognition, Study Results, and New Drug Application - Research Report on Pfizer, Lilly, Regeneron, Vertex, and GSK 9:00 a.m. Nov. 1, 2013 - PR Newswire
In Russia, the Use of Premium-Priced Novel Agents Will Expand the Acute Coronary Syndrome Market Through 2017 10:00 a.m. Oct. 29, 2013 - PR Newswire
Lessons From Hurricane Sandy: American College of Endocrinology (ACE) Urges Those With Diabetes to Plan Ahead 9:50 a.m. Oct. 29, 2013 - BusinessWire
The Alzheimer's Disease Drug Market Will Triple by 2022, Driven Largely by the Projected Launch of Eli Lilly's Solanezumab 9:00 a.m. Oct. 29, 2013 - PR Newswire
FDA Approves Addition to CIALIS® (tadalafil) Product Label 8:00 a.m. Oct. 25, 2013 - PR Newswire
Lilly announces Tapiero retiring; Zulueta promoted to senior vice president and president of Emerging Markets 5:00 p.m. Oct. 24, 2013 - PR Newswire
Critical Alerts For LinkedIn, MasterCard, News Corp, Eli Lilly, and ASML Holdings Released By InvestorsObserver 9:31 a.m. Oct. 24, 2013 - PR Newswire
Returning Value to Shareholders through Dividends, Strong Financial Results, and Regulatory Approvals - Research Report on Lilly, Illumina, Regeneron, Teva, and Vanda Pharmaceuticals 8:00 a.m. Oct. 24, 2013 - PR Newswire
FDA Grants Lilly's Ramucirumab Priority Review as a Potential Single-Agent Treatment for Advanced Gastric Cancer 6:31 a.m. Oct. 23, 2013 - PR Newswire
Lilly Reports Third-Quarter 2013 Results 6:30 a.m. Oct. 23, 2013 - PR Newswire
Jackson Tai Elected to Lilly Board of Directors 10:21 a.m. Oct. 22, 2013 - PR Newswire
Jackson Tai Elected to Lilly Board of Directors 8:00 a.m. Oct. 22, 2013 - PR Newswire
Lilly Declares Fourth-Quarter 2013 Dividend 4:15 p.m. Oct. 21, 2013 - PR Newswire
ZIOPHARM and Intrexon Announce Presentation of Data Highlighting Versatility of Novel Gene Expression and Control Technology 12:30 p.m. Oct. 21, 2013 - GlobeNewswire
The Carlyle Group and AlpInvest Assume Management of Two Indiana Life Sciences Funds of Funds Totaling $130 Million 7:00 a.m. Oct. 17, 2013 - BusinessWire
Awareness Programs, Restructuring Efforts, Conference Calls, Marketing Authorization Withdrawal and Clinical Trial Commencement - Research Report on Lilly, Teva, Elan, Zoetis, and Boston Scientific 8:00 a.m. Oct. 16, 2013 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

U Power's H1 2026: Inside the Financial Numbers

Financial Struggles Amid Expansion Efforts Imagine a ship trying to lift anchor while taking on water. That's U Power Limited's latest financials for the first half of 2026 in a nutshell. We're seeing the company, listed under NASDAQ: UCAR, navigating through turbulent financial seas while executing ambitious expansion projects. Revenue Declines Spell Trouble Total net...

Paris Baguette Pioneers Drive-Thru in Oklahoma

Tapping The Unseen Potential In Bakery Cafes Every so often a business move comes along that makes you sit up and say, "Why the hell haven't they done this before?" Paris Baguette has finally cracked that code, rolling out its first-ever drive-thru in Moore, Oklahoma. Now, imagine yourself zipping through for a croissant without leaving the comfort of your car seat. Makes...

LINC Faces Class Action, Investors Eye November Deadline

Lincoln's Class Action Battle: What's at Stake It's no picnic in the stock-trading trenches, especially with the heat Lincoln Education Services Corporation is catching. The class action suit flashing headlines is a big deal, folks, and it hinges on Lincoln's alleged fibs about student enrollments. With a lead plaintiff deadline looming on November 10, 2026, investors...

Mynd.ai Alters ADS Ratio Affecting Share Dynamics

Analyzing Mynd.ai's ADS Ratio Tweak When Mynd.ai decides to shake things up with the American Depositary Shares (ADS) ratio, it's like they're throwing a curveball straight at Wall Street. Listen up, this isn't just a deck shuffle—it's a fundamental tweak that could play a big role in the stock’s perceived value. Starting December 7, 2027, one ADS will leap from...

SAGA Metals Enters Decision-Making Circles in Canada

Stepping into the Big Leagues Seems like SAGA Metals is making a gutsy move, stepping into some heavy-hitting circles. They just hitched their wagon to the Canadian Chamber of Commerce's Critical Minerals Council. That's not just a foot in the door; that's walking right into the room where national policy gets cooked up. Joining forces here could be their ticket to...

UP Fintech Faces Class Action: Key Investor Impacts

UP Fintech's Tumultuous Ride Ever watch a stock tumble and think, "Here we go again?" That's UP Fintech Holding Limited (NASDAQ:TIGR) right now. It's staring down the barrel of a securities fraud class action lawsuit, and trust me, it's messier than yesterday's lunch special. The stock's already gone through the wringer, dropping a hefty 25.34% after some nasty news from...

CassTime's AI Solution Eases Global Parts Market Strains

Driving Innovation in the Auto Aftermarket When car parts become a global jigsaw puzzle, you need more than wrenches to solve it. Enter CassTime with its AI-driven 'T+D Solution'—a tangible answer to the woes of data matching and repair capability bottlenecks plaguing the automotive aftermarket worldwide. Taming the Global Parts Beast Pull back the curtain on AAPEX 2026...

Detroit Hosts Groundbreaking AquaHacking Challenge

Shaking Up the Water Scene in Detroit Forget Wall Street for a moment—there's a new kind of trading floor where the stakes are nothing less than the health of our waterways. Yesterday, Detroit saw the Great Lakes and St. Lawrence Binational AquaHacking Challenge 2026 wrap up with a bang, having gathered 12 fiery teams on a mission to tackle urgent water issues head-on....

J&J's New Study: Sjögren’s Solution Insight Sparks Debate

Patient-Centric Take on Sjögren's Disease Johnson & Johnson has dropped fresh Phase 2 results on nipocalimab, reminding everyone they're at the helm of reshaping treatments for Sjögren's disease (SjD). A condition leaving about four million folks craving better days, in multiple ways, shines a light on what's gripping patients the hardest. It's hard not to sit up and...

CalExitNow Push for CA GOP Ban & Sovereignty Talks

California's Political Pot Stirs In the wild world of politics, California stands as a fiery beacon yet again. This time, CalExitNow, a fiery group championing California's self-determination, is taking aim at the state’s Republican Party. Reminds me of a stock under pressure—hesitate at your peril as the winds of change sweep through. Disqualification Petition: A...